{
    "Trade/Device Name(s)": [
        "ImmuLisa Enhanced Gliadin IgA Antibody ELISA",
        "ImmuLisa Enhanced Gliadin IgG Antibody ELISA"
    ],
    "Submitter Information": "Immco Diagnostics, Inc.",
    "510(k) Number": "K163177",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MST"
    ],
    "Summary Letter Date": "July 5, 2017",
    "Summary Letter Received Date": "July 7, 2017",
    "Submission Date": "July 27, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.5750"
    ],
    "Regulation Name(s)": [
        "Radioallergosorbent (RAST) immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Gliadin IgA antibody",
        "Gliadin IgG antibody"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microplate reader",
        "Spectrophotometer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme linked immunosorbent assay (ELISA)",
        "Colorimetric detection"
    ],
    "Methodologies": [
        "Solid phase immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Immco ImmuLisa Enhanced Gliadin IgA and IgG ELISA assays for detection of anti-gliadin antibodies in human serum to aid diagnosis of celiac disease or dermatitis herpetiformis.",
    "Indications for Use Summary": "Qualitative or semi-quantitative detection of IgA or IgG anti-gliadin antibodies in human serum to aid in the diagnosis of patients with celiac disease or dermatitis herpetiformis, used with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}